Treatment of tumor cells with the ErbB2 activating ligand heregulin (HRG) induces migration and in siRNA-mediated Memo knock-down (KD) cells, HRG-induced migration is dramatically impaired [1], [2]. Here, HRG is linked to neoplasm.